Axon Enterprise, Inc $AXON Holdings Reduced by Strs Ohio

Strs Ohio lessened its holdings in shares of Axon Enterprise, Inc (NASDAQ:AXON) by 45.0% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 34,784 shares of the biotechnology company’s stock after selling 28,444 shares during the period. Strs Ohio’s holdings in Axon Enterprise were worth $24,962,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the business. Dilation Capital Management LP boosted its position in Axon Enterprise by 64.9% during the 3rd quarter. Dilation Capital Management LP now owns 7,596 shares of the biotechnology company’s stock worth $5,451,000 after acquiring an additional 2,989 shares during the period. Avidian Wealth Enterprises LLC acquired a new position in Axon Enterprise during the 3rd quarter valued at about $1,014,000. Rakuten Investment Management Inc. bought a new stake in shares of Axon Enterprise during the 3rd quarter worth about $1,417,000. Triasima Portfolio Management inc. lifted its stake in shares of Axon Enterprise by 20.3% in the 3rd quarter. Triasima Portfolio Management inc. now owns 9,343 shares of the biotechnology company’s stock worth $6,705,000 after acquiring an additional 1,578 shares during the period. Finally, Americana Partners LLC boosted its holdings in shares of Axon Enterprise by 30.5% in the third quarter. Americana Partners LLC now owns 436 shares of the biotechnology company’s stock valued at $313,000 after acquiring an additional 102 shares in the last quarter. 79.08% of the stock is owned by institutional investors.

Axon Enterprise Stock Up 1.0%

NASDAQ AXON opened at $613.14 on Friday. Axon Enterprise, Inc has a twelve month low of $469.24 and a twelve month high of $885.91. The company has a debt-to-equity ratio of 0.57, a quick ratio of 2.89 and a current ratio of 3.12. The stock has a market cap of $48.38 billion, a PE ratio of 194.03, a PEG ratio of 19.30 and a beta of 1.41. The firm has a 50-day simple moving average of $576.17 and a 200 day simple moving average of $676.14.

Axon Enterprise (NASDAQ:AXON) last announced its quarterly earnings data on Wednesday, November 5th. The biotechnology company reported $1.17 EPS for the quarter, missing analysts’ consensus estimates of $1.63 by ($0.46). The firm had revenue of $710.64 million during the quarter, compared to the consensus estimate of $704.83 million. Axon Enterprise had a return on equity of 4.29% and a net margin of 10.05%.Axon Enterprise’s revenue was up 30.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.45 EPS. On average, research analysts forecast that Axon Enterprise, Inc will post 5.8 EPS for the current year.

Insider Buying and Selling

In other Axon Enterprise news, President Joshua Isner sold 20,000 shares of the firm’s stock in a transaction dated Monday, December 8th. The shares were sold at an average price of $552.60, for a total transaction of $11,052,000.00. Following the completion of the transaction, the president owned 249,502 shares in the company, valued at $137,874,805.20. This trade represents a 7.42% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Jeffrey C. Kunins sold 1,797 shares of the company’s stock in a transaction that occurred on Tuesday, December 2nd. The shares were sold at an average price of $539.23, for a total value of $968,996.31. Following the completion of the sale, the insider owned 83,485 shares in the company, valued at approximately $45,017,616.55. This represents a 2.11% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 60,540 shares of company stock worth $34,684,738. Insiders own 4.40% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the company. Wall Street Zen downgraded Axon Enterprise from a “hold” rating to a “sell” rating in a research report on Saturday, November 8th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Axon Enterprise in a research note on Monday, December 29th. The Goldman Sachs Group lowered their target price on Axon Enterprise from $940.00 to $800.00 and set a “buy” rating on the stock in a report on Wednesday, November 5th. Morgan Stanley reduced their price objective on shares of Axon Enterprise from $760.00 to $713.00 and set an “overweight” rating for the company in a research report on Wednesday, December 17th. Finally, TD Cowen reiterated a “buy” rating on shares of Axon Enterprise in a report on Wednesday, November 5th. Fourteen research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $805.71.

About Axon Enterprise

Axon Enterprise, Inc develops technology and weapons systems for public safety and law enforcement agencies, combining hardware, software and cloud services. The company’s hardware portfolio includes conducted energy weapons (commonly known as TASER devices), body-worn cameras and in-car camera systems. Axon pairs these devices with a suite of connected products and accessories designed to capture, store and manage field evidence.

Beyond hardware, Axon operates a subscription-based software platform for digital evidence management, evidence review and records management.